Skip to main content
. 2022 Feb 9;14(4):863. doi: 10.3390/cancers14040863

Figure 1.

Figure 1

Diagnostic performance of hPG80 in (A) NENs, NEC and NET patient cohorts, (B) by tumor grade, (C) by tumor site as compared to the 18–25-year-old and 50–80-year-old.